TrialOpen forum infectious diseases2024

Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study.

Charlotte-Paige Rolle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.